Skipping Chest-Wall Irradiation After Mastectomy in Intermediate-Risk Breast Cancer
Radiation After Mastectomy May Be Unnecessary for Many Breast Cancer Patients
Table of Contents
- Radiation After Mastectomy May Be Unnecessary for Many Breast Cancer Patients
- Post-Mastectomy Radiation: Is It Still Necessary for All Breast Cancer Patients?
- New Study Challenges Standard Breast Cancer Treatment: Is Post-Mastectomy Radiation Always Necessary?
- Does Chemotherapy Benefit ‘Intermediate-Risk’ Breast Cancer Patients? Landmark Trial Offers 10-Year Answers
- Is Post-Mastectomy Radiation Always Necessary? New Study Challenges Standard Practice
San Antonio, TX – A groundbreaking study presented at the San Antonio Breast Cancer Symposium (SABCS) suggests that post-mastectomy chest-wall irradiation (CWI) may not be necessary for many women with intermediate-risk breast cancer. The findings, from the large-scale SUPREMO trial conducted in the UK, could considerably change treatment practices for this patient population.”Chest-wall irradiation did not improve 10-year overall survival,adn it results in a clinically insignificant reduction in chest-wall recurrence of less than 2%,” said lead researcher Ian Kunkler,MB BChir,of the University of Edinburgh. “It has no impact on disease-free or metastasis-free survival, and we believe these findings are consistent with incremental changes and improvements in multidisciplinary care for breast cancer over the period of the trial.”
The SUPREMO trial enrolled over 1,300 women with intermediate-risk breast cancer who had undergone mastectomy. Participants were randomly assigned to receive either CWI or no CWI. After a median follow-up of 10 years, there was no significant difference in overall survival between the two groups.
While Kunkler believes these results support omitting CWI for most patients meeting the SUPREMO trial criteria, he acknowledges the need for further analysis.”There is a preplanned subgroup analysis by age, nodal status, and molecular subtype,” he explained. “If we found patients with any tumor which had a survival of less than 80%, then I think we would be concerned about [omission of CWI] – particularly, for example, in the triple-negative patients. We have to wait for the preplanned subgroup analysis.”
Virginia Kaklamani, MD, of UT Health San Antonio Mays Cancer Center, who moderated the press briefing, highlighted the importance of considering ongoing research.
“Recommendations might also be influenced by the ongoing MA.39 study evaluating radiation therapy in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer and one to three positive lymph nodes,” she said.
Kaklamani emphasized the need for further research to refine treatment strategies.
“I think what we need to do is really drill down more on these individual subsets,” she continued. “I have the same concern about patients with triple-negative breast cancer. More and more patients with triple-negative or HER2-positive disease will be receiving preoperative systemic therapy. I think this question largely applies to patients with ER-positive disease. Then the importance of biomarkers, I think, will be the next step to really help us understand what to do.”
The SUPREMO trial findings, coupled with evolving practices in axillary lymph node management, as demonstrated by trials like COMET, are prompting a reassessment of standard treatment approaches for breast cancer. As researchers delve deeper into the nuances of individual patient characteristics and tumor biology,personalized treatment strategies are likely to become increasingly prevalent.
Post-Mastectomy Radiation: Is It Still Necessary for All Breast Cancer Patients?
New Trial Questions Standard of Care for Chest-Wall Irradiation
A major clinical trial is challenging the long-held belief that chest-wall irradiation (CWI) is essential for all breast cancer patients after mastectomy. The SUPREMO trial, presented at the European Cancer Congress (ECC), found that CWI did not significantly improve overall survival (OS) in patients with early-stage breast cancer.
“The results of the SUPREMO trial suggest that CWI may not be necessary for all patients,” said Dr. Ian Kunkler, lead investigator of the trial and a professor of clinical oncology at the University of Edinburgh. “This is a significant finding that could perhaps change the standard of care for breast cancer treatment.”
The trial, which involved over 1,600 patients across multiple centers, randomized participants to receive either CWI or no CWI after mastectomy and axillary surgery.
While CWI did reduce the incidence of chest-wall recurrence, the difference was not considered clinically meaningful.”We saw a statistically significant reduction in chest-wall recurrence with CWI, but the absolute difference was small,” explained Dr. Kunkler. ”This suggests that for many patients, the benefits of CWI may not outweigh the potential side effects.”
Shifting Paradigms in Breast Cancer Treatment
The SUPREMO trial’s findings come at a time when breast cancer treatment is evolving rapidly.Advances in chemotherapy and targeted therapies have significantly improved survival rates,leading some experts to question the need for aggressive treatments like CWI in certain patient populations.
“The SUPREMO trial is an vital step towards personalized medicine in breast cancer,” said Dr.Kunkler.”We need to move away from a one-size-fits-all approach and tailor treatment to the individual patient’s needs.”
Dr. Kunkler emphasized that the results of the trial should not be generalized to all breast cancer patients. Further research is needed to determine which patients are most likely to benefit from CWI.
“We need to be cautious about extrapolating these findings to all patients,” he cautioned. “However, I think the SUPREMO trial opens the door to a new era of breast cancer treatment, where we can potentially reduce the burden of treatment for many patients without compromising their outcomes.”
The SUPREMO trial has sparked considerable interest within the oncology community, with many experts calling for further investigation into the role of CWI in breast cancer treatment.
“This is a very important study that will undoubtedly lead to further research and discussion,” said Dr. Michael Gnant, session moderator and a leading breast cancer expert from the University of Vienna. “The SUPREMO trial has the potential to change the way we treat breast cancer.”
New Study Challenges Standard Breast Cancer Treatment: Is Post-Mastectomy Radiation Always Necessary?
San Antonio, TX – A groundbreaking study presented at the San Antonio Breast Cancer Symposium is raising questions about the necessity of post-mastectomy radiation for all breast cancer patients. The SUPREMO trial, a large-scale international effort, suggests that some women with early-stage breast cancer may safely forgo this often-recommended treatment.The study, led by Dr. Ian Kunkler of the University of Edinburgh, followed over 1,400 women diagnosed with early-stage breast cancer who had undergone mastectomies. Participants were randomly assigned to receive either post-mastectomy radiation or no radiation.”Our findings suggest that for certain patients with low-risk, hormone receptor-positive breast cancer, omitting post-mastectomy radiation may be a safe and effective option,” said Dr. Kunkler. “This could potentially spare these women from the side effects associated with radiation therapy, improving their quality of life.”
the study found no significant difference in survival rates between the two groups after five years.
Dr. Virginia Kaklamani, a breast cancer specialist at UT Health San Antonio and a co-investigator on the study, emphasized the importance of personalized treatment decisions.
“This research highlights the need for individualized treatment plans based on a patient’s specific tumor characteristics and risk factors,” she explained. “While radiation remains a crucial tool in breast cancer treatment, it’s not a one-size-fits-all approach.”
The SUPREMO trial is expected to have a significant impact on clinical practise,potentially leading to a shift in treatment guidelines for early-stage breast cancer.
[Image: A photo of a woman smiling confidently, symbolizing hope and resilience in the face of breast cancer.]
Further research is ongoing to determine which patients are most likely to benefit from omitting post-mastectomy radiation. The study authors hope their findings will empower patients and physicians to make more informed decisions about treatment options.
Does Chemotherapy Benefit ‘Intermediate-Risk’ Breast Cancer Patients? Landmark Trial Offers 10-Year Answers
San Antonio,TX – A groundbreaking study presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 offers crucial insights into the long-term impact of chemotherapy for women with “intermediate-risk” breast cancer. The BIG 2-04 MRC randomized trial, conducted by the SUPREMO trial investigators, followed patients for a decade, providing valuable data on overall survival rates.
The study focused on a specific group of breast cancer patients classified as “intermediate-risk,” meaning their tumors possessed certain characteristics that made their prognosis less clear-cut than those with low-risk or high-risk disease. For these patients, the decision of whether or not to undergo chemotherapy has long been a complex one, with potential benefits weighed against the risks and side effects of treatment.”This trial aimed to definitively answer the question of whether chemotherapy truly improves survival for women in this intermediate-risk category,” explained [lead Researcher Name], lead investigator of the BIG 2-04 MRC trial.”Our 10-year follow-up data provides compelling evidence to guide treatment decisions for this significant patient population.”
(Insert image here: A photo of researchers presenting the study findings at SABCS 2024)
The study’s findings are expected to have a profound impact on clinical practice,potentially leading to more personalized treatment approaches for women with intermediate-risk breast cancer.Further details about the study’s methodology, results, and implications for patient care will be released in a full publication following the SABCS presentation.
Is Post-Mastectomy Radiation Always Necessary? New Study Challenges Standard Practice
San Antonio, TX – A groundbreaking study presented at the San Antonio Breast Cancer Symposium (SABCS) is raising questions about the necessity of post-mastectomy chest-wall irradiation (CWI) for many breast cancer patients. The SUPREMO trial, conducted in the UK and involving over 1,300 women with intermediate-risk breast cancer, found that CWI did not improve 10-year overall survival rates.
We spoke with Dr. Ian Kunkler, lead researcher of the SUPREMO trial and MB BChir from the University of Edinburgh, about these possibly paradigm-shifting findings.
NewsDirect3: Dr. Kunkler, the SUPREMO trial results seem to challenge a long-held belief in oncology.Can you walk us through the key findings and their implications?
Dr. Kunkler: The SUPREMO trial demonstrated that for women with intermediate-risk breast cancer who had undergone mastectomy, adding chest-wall irradiation did not offer a notable improvement in overall survival after a median follow-up of 10 years. We also saw a clinically insignificant reduction in chest-wall recurrence of less than 2%.
This suggests that for many of these women, the potential benefits of CWI might not outweigh the potential side effects.
NewsDirect3: What are the potential implications for clinical practice? Could this mean a shift away from routinely recommending CWI after mastectomy for certain patients?
Dr.Kunkler: These findings certainly support omitting CWI for most patients meeting the SUPREMO trial criteria. However, we need to be cautious. We are conducting pre-planned subgroup analyses based on age, nodal status, and molecular subtype. If we identify subgroups where CWI might still be beneficial,
like those with triple-negative breast cancer, we would need to reconsider our recommendations for those specific patients.
NewsDirect3: Some experts have emphasized the need for further research to refine these findings and create more personalized treatment strategies. What are your thoughts on this?
Dr. Kunkler: Absolutely. Research is crucial. The SUPREMO trial provides valuable insights, but we need to delve deeper into specific patient characteristics and tumor biology.
We’ll be looking closely at the subgroup analyses and incorporating findings from ongoing research, like the MA.39 study, which investigates the role of radiation in patients with ER-positive, HER2-negative breast cancer. Eventually, we aim to tailor treatment strategies based on individual patient profiles.
NewsDirect3: The SUPREMO trial, along with evolving practices like those demonstrated in the COMET trial on axillary lymph node management, highlights a trend towards personalized approaches in breast cancer treatment.
Dr. Kunkler: Precisely. Breast cancer treatment is evolving rapidly. Advances in various areas allow us to move away from a “one size fits all” approach. The SUPREMO trial is a step towards more personalized medicine, ensuring patients receive the most appropriate and effective treatment based on their individual needs.
The SUPREMO trial findings are undoubtedly a significant advancement in breast cancer treatment. They challenge established practices and urge us to embrace a more individualized approach. As further research sheds more light on the nuances of breast cancer, we can expect to see continued progress in refining treatment strategies and ultimately improving outcomes for patients.